T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van-der-lelie et al., Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma, N Engl J Med, vol.333, pp.1540-1545, 1995.

E. Kondo, Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma, J Clin Exp Hematop, vol.56, issue.2, pp.100-108, 2016.

C. Gisselbrecht, B. Glass, N. Mounier, D. Gill, D. C. Linch et al., Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era, J Clin Oncol, vol.28, pp.4184-4190, 2010.

N. Mounier, C. Canals, C. Gisselbrecht, J. Cornelissen, R. Foa et al., High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry, Biol Blood Marrow Transplant, vol.18, issue.5, pp.788-93, 2012.

J. R. Passweg, H. Baldomero, P. Bader, G. W. Basak, C. Bonini et al., Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report, Bone Marrow Transplant, vol.53, issue.9, pp.1139-1148, 2018.

V. Pavone, F. Gaudio, A. Guarini, T. Perrone, A. Zonno et al., Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma, Bone Marrow Transplant, vol.29, issue.4, pp.285-90, 2002.

M. A. Gertz, Current status of stem cell mobilization, Br J Haematol, vol.150, issue.6, pp.647-62, 2010.

B. Pocali, D. Simone, M. Annunziata, M. Palmieri, S. et al., epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma, vol.45, pp.1605-1614, 2004.

M. K. Kim, S. Kim, S. S. Lee, S. J. Sym, D. H. Lee et al., Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion, vol.47, pp.1447-54, 2007.

E. Van-den-neste, N. Schmitz, N. Mounier, D. Gill, D. Linch et al., Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study, Bone Marrow Transplant, vol.52, issue.2, pp.216-221, 2017.

B. L. To, D. N. Haylock, P. J. Simmons, and C. A. Juttner, The biology and clinical uses of blood stem cells, Blood, vol.89, pp.2233-58, 1997.

N. Schmitz, D. C. Linch, P. Dreger, A. H. Goldstone, M. A. Boogaerts et al., Randomised trial of filgrastimmobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients, Lancet, vol.347, issue.8998, pp.353-360, 1996.

U. Zahid, F. Akbar, A. Amaraneni, M. Husnain, O. Chan et al., A Review of Autologous Stem Cell Transplantation in Lymphoma, Curr Hematol Malig Rep, vol.12, issue.3, pp.217-226, 2017.

K. Kriegsmann, A. Schmitt, M. Kriegsmann, T. Bruckner, A. Anyanwu et al., Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection, Biol Blood Marrow Transplant, vol.24, issue.6, pp.1281-1288, 2018.

L. A. Marquez-curtis, A. R. Turner, S. Sridharan, M. Z. Ratajczak, and A. Janowska-wieczorek, The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes, Stem Cell Rev, pp.590-607, 2011.

T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage et al., Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, vol.24, pp.3187-3205, 2006.

T. Kuittinen, T. Nousiainen, P. Halonen, E. Mahlamäki, and E. Jantunen, Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma, Bone Marrow Transplant, vol.33, pp.907-919, 2004.

I. Pusic, S. Y. Jiang, S. Landua, G. L. Uy, M. P. Rettig et al., Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation, Biol Blood Marrow Transplant, vol.14, pp.1045-56, 2008.

P. Wuchter, D. Ran, T. Bruckner, T. Schmitt, M. Witzens-harig et al., Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation, Biol Blood Marrow Transplant, vol.16, pp.490-499, 2010.

E. Jantunen, V. Varmavuo, A. Juutilainen, T. Kuittinen, E. Mahlamäki et al., Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use, Ann Hematol, vol.91, pp.1073-1082, 2012.

L. N. Gordan, M. W. Sugrue, J. W. Lynch, K. D. Williams, S. A. Khan et al., Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation, Leuk Lymphoma, vol.44, pp.815-835, 2003.

M. W. Sugrue, K. Williams, B. H. Pollock, S. Khan, S. Peracha et al., Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation, Leuk Lymphoma, vol.39, pp.509-528, 2000.

M. Tomblyn, L. J. Burns, B. Blazar, J. Wagner, C. Lee et al., Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma, Bone Marrow Transplant, vol.40, pp.111-119, 2007.

V. Pavone, F. Gaudio, G. Console, U. Vitolo, P. Iacopino et al., Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation, Bone Marrow Transplant, vol.37, pp.719-743, 2006.

E. Jantunen, T. Kuittinen, E. Mahlamäki, M. Pyörälä, P. Mäntymaa et al., Efficacy of preemptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience, Eur J Haematol, vol.86, pp.299-304, 2011.

A. D'addio, A. Curti, N. Worel, K. Douglas, M. R. Motta et al., The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and GCSF, Bone Marrow Transplant, vol.46, pp.356-363, 2011.

E. Jantunen and R. M. Lemoli, Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept, Transfusion, vol.52, pp.906-914, 2012.

C. Chabannon, F. Bijou, J. M. Miclea, N. Milpied, J. M. Grouin et al., A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the 'ondemand' scheme of administration at French autologous hematopoietic stem cell transplant programs, Transfusion, vol.55, pp.2149-2157, 2015.

N. Worel, G. Fritsch, H. Agis, A. Böhm, G. Engelich et al., Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure, J Clin Apher, vol.32, issue.4, pp.224-234, 2017.

G. Milone, M. Martino, A. Spadaro, S. Leotta, D. Marco et al., Plerixafor on demand combined with chemotherapy and granulocyte colonystimulating factor: significant improvement in peripheral blood stem cell mobilization and harvest with no increase in costs, Br J Haematol, vol.164, pp.113-123, 2014.

B. B. Yang and A. Kido, Pharmacokinetics and pharmacodynamics of pegfilgrastim, Clin Pharmacokinet, vol.50, issue.5, pp.295-306, 2011.

B. Simona, R. Cristina, N. Luca, S. Sara, B. Aleksandra et al., A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy, Transfus Apher Sci, vol.43, issue.3, pp.321-327, 2010.

K. E. Herbert, P. Gambell, E. K. Link, A. Mouminoglu, D. M. Wall et al., Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells, Bone Marrow Transplant, vol.48, issue.3, pp.351-357, 2013.

A. Isidori, M. Tani, F. Bonifazi, P. Zinzani, A. Curti et al., Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients, Haematologica, vol.90, issue.2, pp.225-256, 2005.

A. Nosari, R. Cairoli, D. Ciapanna, L. Gargantini, L. Intropido et al., Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens, Bone Marrow Transplant, vol.38, issue.6, pp.413-419, 2006.

F. Kroschinsky, K. Holig, U. Platzbecker, K. Poppe-thiede, R. Ordemann et al., Efficacy of singledose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma, Transfusion, vol.46, pp.1417-1423, 2006.

N. Russell, R. Mesters, J. Schubert, M. Boogaerts, H. E. Johnsen et al., A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy, Haematologica, vol.93, issue.3, pp.405-417, 2008.

L. J. Costa, C. Kramer, K. R. Hogan, C. D. Butcher, A. L. Littleton et al., Pegfilgrastim-versus filgrastimbased autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis, Transfusion, vol.52, issue.11, pp.2375-81, 2012.

J. Desoutter, C. Ossart, M. N. Lacassagne, A. Regnier, J. P. Marolleau et al., Cryopreservation and thawing of hematopoietic stem cell CD34-induced apoptosis through caspase pathway activation: Key role of granulocytes, Cytotherapy, vol.21, issue.6, pp.612-618, 2019.

J. W. Kuan, A. T. Su, S. P. Wong, X. Y. Sim, S. G. Toh et al., A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization, Transfus Apher Sci, vol.53, issue.2, pp.196-204, 2015.

R. Ria, A. Reale, A. Melaccio, V. Racanelli, F. Dammacco et al., lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies, Clin Exp Med, vol.15, issue.2, pp.145-50, 2015.

J. Montoro, G. Andreola, A. Gardellini, A. Babic, M. Negri et al., R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma, Transfus Apher Sci, vol.50, issue.3, pp.411-415, 2014.

V. Varmavuo, J. Rimpiläinen, H. Kuitunen, A. Nihtinen, K. Vasala et al., Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients, Transfusion, vol.54, issue.5, pp.1243-50, 2014.

A. Partanen, J. Valtola, A. Ropponen, K. Vasala, K. Penttilä et al., Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly, Ann Hematol, vol.96, issue.11, pp.1897-1906, 2017.

A. Partanen, J. Valtola, A. Ropponen, H. Kuitunen, O. Kuittinen et al., Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients, Transfusion, vol.59, issue.1, pp.325-334, 2019.

F. Willis, D. Theti, S. Dean, P. Bacon, N. Baker et al., Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours, Bone Marrow Transplant, vol.42, issue.3, pp.167-73, 2008.

F. Willis, P. Woll, D. Theti, H. Jamali, P. Bacon et al., Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours, Bone Marrow Transplant, vol.43, issue.12, pp.927-961, 2009.

I. Bruns, U. Steidl, R. Kronenwett, R. Fenk, T. Graef et al., A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma, Transfusion, vol.46, issue.2, pp.180-185, 2006.

S. Fruehauf, J. Klaus, J. Huesing, M. R. Veldwijk, E. C. Buss et al., Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma, Bone Marrow Transplant, vol.39, issue.12, pp.743-50, 2007.

G. Tricot, B. Barlogie, M. Zangari, F. Van-rhee, A. Hoering et al., Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy, Haematologica, vol.93, issue.11, pp.1739-1781, 2008.

M. B. Abid, D. Mel, S. Abid, M. A. Yap, E. S. Gopalakrishnan et al., Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction, Clin Lymphoma Myeloma Leuk, vol.18, issue.3, pp.174-179, 2018.

M. G. Kim, N. Han, E. K. Lee, and T. Kim, Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis, Bone Marrow Transplant, vol.50, issue.4, pp.523-553, 2015.

B. D. Cheson, R. I. Fisher, S. F. Barrington, F. Cavalli, L. H. Schwartz et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, vol.32, issue.27, pp.3059-68, 2014.

D. Barnett, V. Granger, I. Storie, J. Peel, R. Pollitt et al., Quality assessment of CD34+ stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation, Br J Haematol, vol.102, issue.2, pp.553-65, 1998.

E. Standard, EBMT. JACIE Standard 7

S. Serke and H. E. Johnsen, A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts, Bone Marrow Transplant, vol.27, issue.5, pp.463-70, 2001.

B. Pope, K. Mitsakos, A. Bilgin, B. Hokin, and R. Grant, Predicting overall viability of cord blood harvests, Transfusion, vol.52, pp.1079-85, 2012.

E. Jantunen, V. Varmavuo, J. Pelkonen, and J. Valtola, Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients, Leuk Lymphoma, vol.7, pp.1-7, 2019.

P. Wuchter, D. Ran, T. Bruckner, T. Schmitt, M. Witzens-harig et al., Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation, Biol Blood Marrow Transplant, vol.16, pp.490-499, 2010.

U. Narayanasami, R. Kanteti, J. Morelli, A. Klekar, A. Al-olama et al., Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation, Blood, vol.98, issue.7, pp.2059-64, 2001.

M. André, E. Baudoux, D. Bron, J. L. Canon, D. Hondt et al., Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies, Transfusion, vol.43, issue.1, pp.50-57, 2003.

R. Ria, T. Gasparre, G. Mangialardi, A. Bruno, G. Iodice et al., Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs, Bone Marrow Transplant, vol.45, issue.2, pp.277-81, 2010.

F. Bijou, Z. Ivanovic, J. M. Boiron, and F. Nicolini, Mobilisation des cellules souches hématopoïétiques : état de l'art en 2011 et perspectives, Transfus Clin Biol, vol.18, issue.5-6, pp.503-518, 2011.

E. Foïs, M. Desmartin, S. Benhamida, F. Xavier, V. Vanneaux et al., Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant, vol.40, pp.831-836, 2007.

R. Reich-slotky, A. I. Colovai, M. Semidei-pomales, N. Patel, M. Cairo et al., Determining post-thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity. Vox Sang, vol.94, pp.351-358, 2008.

. Ojeda-uribe-m1, H. Sovalat, D. Bourderont, A. Brunot, A. Marr et al., Peripheral blood and BM CD34+ CD38-cells show better resistance to cryopreservation than CD34+ CD38+ cells in autologous stem cell transplantation, Cytotherapy, vol.6, issue.6, pp.571-83, 2004.

I. Bruns, U. Steidl, J. C. Fischer, A. Czibere, G. Kobbe et al., Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor, Haematologica, vol.93, issue.3, pp.347-55, 2008.

S. Lee, S. Kim, H. Kim, E. J. Baek, H. Jin et al., Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation. Vox Sang, vol.94, pp.146-52, 2008.

D. S. Allan, M. Keeney, K. Howson-jan, J. Popma, K. Weir et al., Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation, Bone Marrow Transplant, vol.29, issue.12, pp.967-72, 2002.

A. Brand, H. Eichler, Z. M. Szczepiorkowski, J. R. Hess, R. Kekomaki et al., Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise, Transfusion, vol.48, issue.3, pp.546-555, 2008.

J. D. Lickliter, C. G. Begley, A. W. Boyd, J. Szer, and A. P. Grigg, Combined chemotherapy and granulocyte colonystimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients, Leuk Lymphoma, vol.15, issue.1-2, pp.91-98, 1994.

C. H. Weaver, B. Hazelton, R. Birch, P. Palmer, C. Allen et al., An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy, Blood, vol.86, issue.10, pp.3961-3970, 1995.

F. Shojaei, J. Trowbridge, L. Gallacher, L. Yuefei, D. Goodale et al., Cell development. Hierarchical and ontogenic positions serve to define the molecular basis of human hematopoietic stem cell behavior, Dev Cell, vol.8, issue.5, pp.651-63, 2005.

L. Wu, A. Al-hejazi, L. Filion, R. Ben, M. Halpenny et al., Increased apoptosis in cryopreserved autologous hematopoietic progenitor cells collected by apheresis and delayed neutrophil recovery after transplantation: a nested case-control study, Cytotherapy, vol.14, pp.205-219, 2012.

J. F. Abrahamsen, T. Wentzel-larsen, and O. Bruserud, Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg, Cytotherapy, vol.6, issue.4, pp.356-62, 2004.

A. A. Novik, T. I. Ionova, G. Gorodokin, A. Smolyaninov, and B. V. Afanasyev, The Maximow 1909 centenary: A reappraisal. Cellular Therapy and Transplantation, vol.12, pp.1-3, 2009.

E. E. Osgood, M. C. Riddle, and T. J. Matthews, Aplastic anemia treated with daily transfusions and intravenous marrow. Case report, Ann Intern, vol.13, pp.357-67, 1939.

E. D. Thomas, H. L. Loche, W. C. Lu, and J. W. Ferrebee, Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy, N Engl J Med, vol.257, issue.11, pp.491-497, 1957.

J. A. Cavins, S. Kasakura, E. D. Thomas, and J. W. Ferrebee, Recovery of lethally irradiated dogs following infusion of autologous marrow stored at low temperature in dimethylsulphoxide, Blood, vol.20, pp.730-734, 1962.

D. E. Pegg, J. G. Humble, and K. A. Newton, The clinical application of bone marrow grafting, Br J, vol.16, pp.417-452, 1962.

R. Storb, HSCT: Historical Perspective, pp.3-11, 2018.

G. Mathé, J. L. Amiel, and L. Schwarzenberg, Adoptive Immunotherapy of Acute Leukemia: Experimental and Clinical Results, Cancer Res, vol.25, pp.1525-1531, 1965.

J. E. Till and E. A. Mcculloch, A direct measurement of the radiation sensitivity of normal mouse bone marrow cells, Radiat Res, vol.14, pp.213-235, 1961.

A. Mj, Preservation of mouse bone marrow at -79 degrees C. with dimethyl sulphoxide, Nature, vol.190, pp.1204-1209, 1961.

E. D. Thomas and R. Storb, Technique for human marrow grafting, Blood, vol.36, issue.4, pp.507-522, 1970.

E. D. Thomas, C. D. Buckner, and R. H. Rudolph, Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs, Blood, vol.38, issue.3, pp.267-287, 1971.

J. L. Gray and W. A. Robinson, In vitro colony formation by human bone marrow cells after freezing, J Lab Clin Med, vol.81, issue.2, pp.317-339, 1973.

A. H. Ragab, E. Gilkerson, M. Myers, and S. C. Choi, The culture of colony forming units from the peripheral blood and bone marrow of children with acute lymphocytic leukemia, Cancer, vol.34, issue.3, pp.663-672, 1974.

F. R. Appelbaum, G. P. Herzig, and J. L. Ziegler, Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma, Blood, vol.52, pp.85-95, 1978.

, Report of an international cooperative study, Lancet, vol.2, pp.960-962, 1986.

J. W. Goodman and G. S. Hodgson, Evidence for stem cells in the peripheral blood of mice, Blood, vol.19, pp.702-716, 1962.

R. Storb, T. C. Graham, R. B. Epstein, G. E. Sale, and E. D. Thomas, Demonstration of hemopoietic stem cells in the peripheral blood of baboons by cross circulation, Blood, vol.50, pp.537-579, 1977.

A. Kessinger, J. O. Armitage, J. D. Landmark, and D. D. Weisenburger, Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells, Exp Hematol, vol.14, issue.3, pp.192-198, 1986.

C. I. Civin, L. C. Strauss, C. Brovall, M. J. Fackler, J. F. Schwartz et al., Antigenic analysis of hematopoiesis: III. A hematopoietic progenitor cell surface antigen defined by monoclonal antibody raised against KG-la cells, Journal of Immunology, vol.133, pp.157-165, 1984.

C. M. Richman, R. S. Weiner, and R. A. Yankee, Increase in circulating stem cells following chemotherapy in man, Blood, vol.47, pp.1031-1040, 1976.

U. Duhrsen, J. L. Villeval, J. Boyd, G. Kannourakis, G. Morstyn et al., Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients, Blood, vol.72, pp.2074-81, 1988.

R. Kanteti, K. Miller, and J. Mccann, Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: A clinical and molecular analysis, Bone Marrow Transplant, vol.24, pp.473-81, 1999.

J. M. Vose, G. Sharp, and W. C. Chan, Autologous transplantation for aggressive non-Hodgkin's lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease, J Clin Oncol, vol.20, pp.2344-52, 2002.

T. J. Smith, B. E. Hillner, N. Schmitz, D. C. Linch, P. Dreger et al., Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma, J Clin Oncol, vol.15, issue.1, pp.5-10, 1997.

A. Clément, C. Coffe, J. C. Adjizian, F. Villard, D. Jolly et al., Collection de cellules souches périphériques, recherche de facteurs prédictifs: une étude multicentrique, Transfus Clin Biol, vol.7, issue.5, pp.485-96, 2000.

L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill et al., The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, vol.109, pp.1857-617, 2007.

N. Schmitz, B. Pfistner, M. Sextro, M. Sieber, A. M. Carella et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, vol.359, issue.9323, pp.2065-71, 2002.

C. Chabannon, A. Corroller, F. Viret, C. Eillen, C. Faucher et al., Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation Leukemia, pp.811-824, 2003.

M. M. Bortin, A compendium of reported human bone marrow transplants, Transplantation, vol.9, pp.571-87, 1970.

J. D. Lickliter, C. G. Begley, A. W. Boyd, J. Szer, and A. P. Grigg, Combined chemotherapy and granulocyte colonystimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients, Leuk Lymphoma, vol.15, issue.1-2, pp.91-98, 1994.